（文章来源：证券日报） 证券日报网讯 2月25日，金城医药发布公告称，公司全资子公司北京金城泰尔制药有限公司及上海金城 素智药业有限公司分别收到国家药品监督管理局下发的比索洛尔氨氯地平片、头孢地尼干混悬剂《药品 注册证书》。 ...

Group 1: Financial Performance Highlights - Lante Optics achieved a revenue of 1.536 billion yuan in 2025, a year-on-year increase of 48.52%, with a net profit of 388 million yuan, up 76.09% [1] - United Imaging reported a revenue of 13.82 billion yuan for 2025, reflecting a 34.18% year-on-year growth, and a net profit of 1.888 billion yuan, up 49.60% [2] - Hengxuan Technology's revenue reached 3.525 billion yuan, an 8.02% increase, with a net profit of 588 million yuan, up 27.75% [3] - Nanya New Materials reported a significant net profit increase of 378.65%, reaching 241 million yuan, with revenue of 5.228 billion yuan, up 55.52% [4] - Yancoal Australia, a subsidiary of Yancoal Energy, reported a revenue of 5.949 billion AUD and a net profit of 4.4 billion AUD for 2025 [5] - Hanlan Co. reported a revenue of 10.467 billion yuan, a 13.04% increase, but a net profit decline of 9.59% to 592 million yuan [10][11] - Transsion Holdings experienced a revenue decline of 4.50% to 65.623 billion yuan, with a net profit drop of 53.43% to 2.584 billion yuan [14] - Huachuang Technology achieved a revenue of 628 million yuan, a 2.78% increase, with a net profit of 42.678 million yuan, up 89.45% [21] - Aiko Optoelectronics reported a revenue of 440.311 million yuan, a 77.36% increase, with a net profit of 64.0919 million yuan, up 307.63% [34] - Chip Microelectronics achieved a revenue of 1.408 billion yuan, a 47.61% increase, with a net profit of 290 million yuan, up 80.42% [35] - Shenkong Co. reported a revenue of 443 million yuan, a 46.26% increase, with a net profit of 101 million yuan, up 146.54% [36] - Qinda Environmental reported a revenue of 2.042 billion yuan, a 55.42% increase, with a net profit of 181 million yuan, up 94.62% [39] Group 2: Corporate Developments - Huilong New Materials announced that its actual controller is planning a significant matter that may lead to a change in company control, resulting in a stock suspension [6] - Fangzheng Securities disclosed that its shareholder China Cinda did not reduce its shareholding as planned during the designated period [7] - Lingyi Technology plans to invest 20 million yuan in a partnership with several investment firms [8] - Longbai Group's subsidiary has partially resumed production after a safety incident [9] - Fuda Co. plans to reduce its repurchased shares by up to 1% through centralized bidding [13] - Fuxing Pharmaceutical's subsidiary received approval for clinical trials of a new drug for lung cancer [15] - Beixin Road and Bridge won a bid for a highway reconstruction project worth 751 million yuan [16] - Songsheng Co. established a joint venture with a registered capital of 30 million yuan, focusing on digital energy products [17] - Moxinlin reported a revenue of 577 million yuan, a 20.98% increase, with a net profit of 55.8745 million yuan, up 22.69% [18] - Zhuhai Beer reported a revenue of 5.878 billion yuan, a 2.56% increase, with a net profit of 903 million yuan, up 11.42% [24] - Honghua Digital reported a revenue of 2.308 billion yuan, a 28.90% increase, with a net profit of 529 million yuan, up 27.63% [25] - Xinfeng Pharmaceutical received FDA approval for two injectable drugs [26] - Jiazhe New Energy's project for green hydrogen production received regulatory approval [27] - Chip Microelectronics reported a revenue of 5.24 billion yuan, a 29.48% increase, with a net profit of 302 million yuan, up 36.1% [28] - Debang Co. completed the cash settlement process for its delisting [29] - Xingfu Electronics reported a revenue of 1.475 billion yuan, a 29.72% increase, with a net profit of 208 million yuan, up 30.37% [30] - Longda Food announced the resignation of its general manager due to work adjustments [31] - Bohai Chemical reported that some fundraising projects have commenced production [32] - Shengke Communication reported a net loss of 150 million yuan for 2025 [33] - Jin Cheng Pharmaceutical's subsidiaries received drug registration certificates for two products [37] - Jinpu Titanium Industry announced the resumption of production at its subsidiary [38] - Zhigao Electric's subsidiary won a bid for a project worth 182 million yuan [40]

每经AI快讯，金城医药2月25日晚间发布公告称，山东金城医药集团股份有限公司之全资子公司北京金 城泰尔制药有限公司及上海金城素智药业有限公司分别收到国家药品监督管理局下发的比索洛尔氨氯地 平片、头孢地尼干混悬剂《药品注册证书》。包括"比索洛尔氨氯地平片"等产品。 （记者 曾健辉） 每经头条（nbdtoutiao）——伤亡180万人！俄乌冲突四周年，陷入谈判死局、战场僵局、经济困局！谁 为战争买单 ...

格隆汇2月25日丨金城医药(300233.SZ)公布，公司之全资子公司北京金城泰尔制药有限公司（简称"金 城泰尔"）及上海金城素智药业有限公司（简称"金城素智"）分别收到国家药品监督管理局下发的比索 洛尔氨氯地平片、头孢地尼干混悬剂《药品注册证书》。比索洛尔氨氯地平片为比索洛尔和氨氯地平组 成的复方制剂，作为高血压治疗的替代疗法，用于同时服用与复方制剂剂量相同的单药且血压控制良好 的患者。头孢地尼干混悬剂为口服抗感染药物，用于治疗由指定微生物的敏感菌株引起的轻度至中度感 染的儿童患者。 ...

【金城医药（维权）：子公司两款产品收到药品注册证书】智通财经2月25日电，金城医药(300233.SZ) 公告称，公司全资子公司金城泰尔和金城素智分别收到国家药品监督管理局下发的比索洛尔氨氯地平片 和头孢地尼干混悬剂的《药品注册证书》。比索洛尔氨氯地平片为高血压治疗的替代疗法，头孢地尼干 混悬剂为口服抗感染药物。这两个产品的获批将进一步丰富公司产品线，并为后续其他产品研发积累经 验。然而，药品销售受市场环境等不确定因素影响，投资者需注意风险。 转自：智通财经 ...

产品 名称 剂型 注册 分类 产品规格 包 装 规 格 药品批准文 号 上市许可持 有人 审批结论 比索 洛尔 氨氯 地平 片 片剂 化学 药品4 类 富马酸比 索洛尔 5mg 与苯磺酸 氨氯地平 （按氨氯 地平计） 5mg 10 片/ 板， 1 板 /盒 国药准字 H20263409 金城泰尔 根据《中华人民共和国 药品管理法》及有关规 定，经审查，本品符合 药品注册的有关要求， 批准注册，发给药品注 册证书。质量标准、说 明书、标签及生产工艺 照所附执行。药品生产 企业应当符合药品生 产质量管理规范要求 方可生产销售。 头孢 地尼 干混 悬剂 口服 混悬 剂 化学 药品3 类 3.0g 1 瓶 /盒 国药准字 H20263374 金城素智 一、药品基本情况 药店销售数据分别是 438 万元人民币、1,428 万元人民币、2,410 万元人民币。 证券代码：300233 证券简称：金城医药 公告编号：2026-009 山东金城医药集团股份有限公司 关于子公司收到药品注册证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 山东金城医药集团股份有限公司之 ...

Core Insights - Company plans to select seven products, including Ceftriaxone Sodium Injection, in the national drug centralized procurement, which is expected to enhance its market share in core antibiotic products [1][2] - The sales revenue of these products is approximately 414 million yuan, accounting for 21.45% of the company's total revenue for the first three quarters of 2025 [1][2] - The procurement cycle is anticipated to run from the end of March 2026 to the end of December 2028 [2] Recent Events - On February 11, 2026, the company announced that its subsidiaries are set to be selected for the procurement of seven products, which will help consolidate its market position [2] - The company’s subsidiary, Guangdong Jincheng Jinsuo Pharmaceutical Co., Ltd., has been re-certified as a high-tech enterprise, which may provide tax benefits and policy support for three years [2] - As of January 30, 2026, the number of shareholders has slightly increased to 29,200, reflecting a 0.31% growth, with an average shareholding value rising by 1.68% [2] Stock Performance - Over the past week (February 6 to 12, 2026), the company's stock price fluctuated between 15.30 yuan and 15.29 yuan, with a slight overall decline and a price range fluctuation of 2.32% [3] - As of February 12, 2026, the stock price was 15.29 yuan, down 1.55%, underperforming the pharmaceutical and biotechnology sector, which fell by 0.60% [3] - Recent capital flow indicates a net outflow of major funds, with a net outflow of 8.5 million yuan on February 12, while small and medium-sized investments showed a net inflow, indicating higher retail investor participation [3]

Core Viewpoint - Jincheng Pharmaceutical announced that its subsidiaries participated in the national procurement bidding for expiring products, with seven products, including Cefotaxime Sodium Injection, expected to be selected, which could significantly impact the company's revenue [1] Group 1: Company Announcement - Jincheng Pharmaceutical's subsidiary, Jincheng Jinsu, and its wholly-owned subsidiary, Jincheng Suzhi, are participating in the national procurement bidding for products whose agreements are expiring [1] - The seven products expected to be selected are projected to generate sales of 414 million yuan before the third quarter of 2025, accounting for 21.45% of the company's revenue [1] - The results of the selection are anticipated to be finalized by the end of March 2026, with the procurement cycle lasting until December 31, 2028 [1]

Core Viewpoint - Jincheng Pharmaceutical announced that its subsidiaries participated in the national centralized procurement for expiring drug agreements, with seven products, including Cefoperazone Sodium Injection and Ceftazidime Injection, expected to be selected for procurement [1] Group 1: Company Performance - The total sales revenue of the seven products expected to be selected for procurement in the first three quarters of 2025 is projected to be 414.46 million yuan, accounting for 21.45% of the company's total revenue during the same period [1] Group 2: Procurement Details - The procurement results are expected to be implemented by the end of March 2026, with the procurement cycle lasting until December 31, 2028 [1] - Medical institutions will prioritize the use of the selected drugs during the procurement cycle, ensuring the completion of the agreed procurement volume [1]

Core Viewpoint - Jincheng Pharmaceutical announced that its subsidiary, Guangdong Jincheng Jinsuo Pharmaceutical Co., Ltd., and its wholly-owned subsidiary, Shanghai Jincheng Suzhi Pharmaceutical Co., Ltd., participated in the bidding for the continuation procurement organized by the National Organization for the procurement of drugs whose agreements have expired [1] Group 1 - The company is involved in the bidding process for seven drug varieties, including Cefotaxime Sodium Injection and Ceftazidime Injection, as part of the national procurement program [1]